The biology and key role of NAD molecules in human metabolism has been well known for decades, but measuring them has been devilishly difficult. NADMED has now brought to market an accurate, fast, scalable, and well protected method to do just that. The assay enables research in large human cohorts, leading to a rapidly increasing number of clinical applications. NADMED already services clinical practitioners, researchers and drug development companies.

 

  • Founding year:
  • 2022
  • Development phase:
  • Market-ready
  • Funding stage:
  • Pre-seed
  • Website:
  • Contact person info:
  • jari.narhi(at)nadmed.fi
  • Team members:
  • 5
  • Article:
  • Read an article about NADMED.